News By Tag
News By Location
Follow on Google News
Partners4Access To Host Webinar On EU Market Access Developments in 2021
The webinar titled ` EU Market Access 2021:What's in store for Orphan Drugs and ATMPs?' will be conducted by educational webinars provider Xtalks and will be held on Wednesday, January 13, 2021 at 11am EDT (4pm BST/UK). For more information or to register for this event, visit EU Market Access 2021: What's in Store for Orphan Drugs and ATMPs? (https://xtalks.com/
Speakers include P4A's managing partner Sophie Schmitz and trade body EUCOPE's secretary general Alexander Natz who will provide the biotech industry perspective at the discussion.
2021 has the potential to be a record year for orphan drugs and advanced therapy medicinal products (ATMPs) in Europe. With the hope of a world in which COVID-19 is a manageable disease comes the promise of ground-breaking new therapies and innovative approaches to digital healthcare.
However, these will enter into an access environment under turmoil and change: a new EU Pharmaceutical Strategy, potential changes to orphan drug legislation and continual evolution of health technology assessment (HTA) processes and digital healthcare. The global population is now on the edge of a major shift in healthcare access, delivery, and engagement. It is time to adapt or crash.
In this webinar, the featured speakers will bring a fresh, forward-looking perspective to the changing regulatory environment in Europe for orphan drugs and ATMPs and the key access trends expected in 2021. Through a mix of case examples and direct experiences, they will highlight insights into likely changes as a result of a greater number of ATMPs seeking commercialisation, the EU Pharmaceutical Strategy, and associated changes to the orphan drug legislation.
Importantly, the webinar panellists will recommend key considerations for manufacturers to optimise preparation of future orphan drug and ATMP launches.
Partners4Access are experts in orphan drug, cell and gene therapy access, partnering with the biotechnology industry to support launches worldwide. Our services focus on five key areas: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence.
As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access. Through various media initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please visit P4A's website: www.partners4access.com or email at email@example.com.